PRNewsWire
10 Jun 2026, 07:05 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
SciBase has enrolled the first patient in the DETECT-AD study to assess the ability of its Electrical Impedance Spectroscopy (EIS) method to predict atopic dermatitis flares. — The commencement of a clinical study is a positive catalyst for a med-tech company as it marks progress toward potential commercial validation of its technology.
+0.30SciBase is conducting the DETECT-AD study in collaboration with Castle Biosciences. — Partnerships with other industry players can provide strategic validation and shared resources, reducing individual operational risk.
+0.20Which stocks this story touches
The company announced the successful first patient enrollment in a clinical study to predict atopic dermatitis flares.
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is collaborating on a clinical study to improve the management of chronic skin conditions.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
Seeking Alpha
2h ago
